Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in Int J Hematol Retrieve available abstracts of 175 articles: HTML format

Single Articles

September 2026
1. URESHINO H
   Road to treatment-free remission in chronic myeloid leukemia.
   Int J Hematol. 2026 Sep 11. doi: 10.1007/s12185-026-04278.
   PubMed     Abstract available
   
   
   
2. NAKATA Y, Hiratsuka A, Yoroidaka T, Takahashi W, et al
   Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.
   Int J Hematol. 2026;124:443-446.
   PubMed     Abstract available
   
   
   
3. KOIZUMI R, Takagi S, Nishida A, Kuno M, et al
   Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study.
   Int J Hematol. 2026;124:328-333.
   PubMed     Abstract available
   
   
   
4. SHIMOSATO Y, Goyama S
   NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives.
   Int J Hematol. 2026;124:303-310.
   PubMed     Abstract available
   
   
   
5. IDA N, Okura M, Tanaka S, Hosono N, et al
   Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.
   Int J Hematol. 2026;124:348-360.
   PubMed     Abstract available
   
   
   August 2026
6. ILORI EO, Kandathil A, Chen W
   Unusual presentation of hairy cell leukemia as a retroperitoneal nodal mass: a diagnostic pitfall.
   Int J Hematol. 2026 Aug 31. doi: 10.1007/s12185-026-04274.
   PubMed    
   
   
   
7. MIZUTA S, Kobayashi K, Kawata T, Ohashi Y, et al
   Dimensionality reduction enables MRD visualization in single-sample flow cytometric analysis in acute leukemia.
   Int J Hematol. 2026 Aug 17. doi: 10.1007/s12185-026-04268.
   PubMed     Abstract available
   
   
   
8. KASHIMURA M, Fujioka Y, Guo YM, Takahashi T, et al
   Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.
   Int J Hematol. 2026;124:295-301.
   PubMed     Abstract available
   
   
   
9. IMAHASHI N, Konuma T, Kobayashi S, Watanabe M, et al
   Are matched-related donors always the best choice? A retrospective study exploring the potential of umbilical cord blood.
   Int J Hematol. 2026;124:262-269.
   PubMed     Abstract available
   
   
   
10. FUJII F, Onozawa M, Yoshida S, Miyashita N, et al
    Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.
    Int J Hematol. 2026;124:167-176.
    PubMed     Abstract available
    
    
    
11. HIRAO T, Yamamoto H, Kuno M, Watanabe O, et al
    Cord blood versus matched related donor transplantation in AML not in remission: role of pre-engraftment immune reactions.
    Int J Hematol. 2026;124:270-282.
    PubMed     Abstract available
    
    
    July 2026
12. ABUMIYA M, Takahashi N
    Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.
    Int J Hematol. 2026 Jul 14. doi: 10.1007/s12185-026-04254.
    PubMed     Abstract available
    
    
    
13. MATSUI H, Takizawa J, Kojima K, Tauchi T, et al
    Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".
    Int J Hematol. 2026 Jul 14. doi: 10.1007/s12185-026-04253.
    PubMed    
    
    
    
14. TAKAHASHI N, Kimura S, Matsuki E, Ono T, et al
    Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.
    Int J Hematol. 2026;124:96-103.
    PubMed     Abstract available
    
    
    May 2026
15. JAYASWAL RP, Badyal RK, Ranawat RK
    Letter comments on: "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan".
    Int J Hematol. 2026 May 13. doi: 10.1007/s12185-026-04226.
    PubMed    
    
    
    
16. KATSUKI K, Miyazaki T, Komaki M, Saigusa Y, et al
    Personalized multivariable clinical prognostic model for patients with acute myeloid leukemia receiving intensive chemotherapy.
    Int J Hematol. 2026 May 12. doi: 10.1007/s12185-026-04222.
    PubMed     Abstract available
    
    
    
17. YANADA M, Shimomura Y, Yamasaki S, Mizuno S, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in Japan: changes in practice patterns and outcomes during the past 20 years.
    Int J Hematol. 2026 May 4. doi: 10.1007/s12185-026-04223.
    PubMed     Abstract available
    
    
    
18. YOKOYAMA H, Yanada M, Mizuno S, Uchida N, et al
    Prognostic factors influencing outcomes of allogeneic HCT for AML with monosomal karyotype.
    Int J Hematol. 2026;123:746-755.
    PubMed     Abstract available
    
    
    
19. YOKOTA A, Munakata W, Kiguchi T, Ogawa Y, et al
    A phase I/II study of tagraxofusp in Japanese patients with blastic plasmacytoid dendritic cell neoplasm.
    Int J Hematol. 2026;123:708-719.
    PubMed     Abstract available
    
    
    April 2026
20. YOKOYAMA S, Onozawa M, Kimura H, Ara T, et al
    Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.
    Int J Hematol. 2026 Apr 22. doi: 10.1007/s12185-026-04212.
    PubMed     Abstract available
    
    
    
21. TAZOE K, Nakamae H, Makuuchi Y, Kuno M, et al
    Ten-color multicolor flow cytometry-based measurable residual disease at pre-transplantation predicts relapse of acute myeloid leukemia: a prospective study.
    Int J Hematol. 2026 Apr 7. doi: 10.1007/s12185-026-04207.
    PubMed     Abstract available
    
    
    
22. HIRAMATSU Y, Urata S, Ishikawa T, Yamauchi T, et al
    A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE.
    Int J Hematol. 2026;123:509-515.
    PubMed     Abstract available
    
    
    
23. SHICHIJO T, Yasunaga JI
    Viral-driven oncogenesis in T/NK-cell lymphomas: parallels and divergences between HTLV-1 and EBV.
    Int J Hematol. 2026;123:476-486.
    PubMed     Abstract available
    
    
    March 2026
24. YAMAGUCHI K, Aoki M, Osako R
    Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04199.
    PubMed     Abstract available
    
    
    
25. OGASAWARA F, Minami Y, Chi S, Ueda T, et al
    Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01/02 study.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04192.
    PubMed     Abstract available
    
    
    
26. IZUMI A, Tachibana T, Miyazaki T, Takeda T, et al
    Safety and efficacy of clofarabine for preconditioning intervention in patients undergoing allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphoblastic leukemia.
    Int J Hematol. 2026 Mar 31. doi: 10.1007/s12185-026-04201.
    PubMed     Abstract available
    
    
    
27. YOSHINARI H, Kawahara Y, Niijima H, Aoki S, et al
    Acute megakaryoblastic leukemia with RBM15::MKL1 fusion presenting as neonatal acute liver failure: rescued by living-donor liver transplantation.
    Int J Hematol. 2026 Mar 24. doi: 10.1007/s12185-026-04194.
    PubMed     Abstract available
    
    
    
28. NOSAKA K
    Recent progress in T-cell malignancies including adult T-cell leukemia-lymphoma.
    Int J Hematol. 2026 Mar 23. doi: 10.1007/s12185-026-04197.
    PubMed     Abstract available
    
    
    
29. TSUTSUMI H, Inoshita N, Tanabe N, Sekiguchi Y, et al
    Central nervous system involvement in plasma cell neoplasms: a rare presentation illustrated by three cases.
    Int J Hematol. 2026;123:459-465.
    PubMed     Abstract available
    
    
    
30. TAKIZAWA J, Yoshida I, Ogawa Y, Toubai T, et al
    A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL.
    Int J Hematol. 2026;123:375-384.
    PubMed     Abstract available
    
    
    
31. SAIKA W, Yamazaki H, Tanaka S, Lin M, et al
    BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.
    Int J Hematol. 2026;123:342-355.
    PubMed     Abstract available
    
    
    February 2026
32. MIYAZAKI Y, Matsumura I, Arita T, Fukuda R, et al
    Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan.
    Int J Hematol. 2026 Feb 26. doi: 10.1007/s12185-026-04181.
    PubMed     Abstract available
    
    
    
33. ISHIDA H, Suenobu S, Imamura T, Shiwaku T, et al
    Outcomes of children with T-cell acute lymphoblastic leukemia treated with the JACLS T-02 protocol.
    Int J Hematol. 2026 Feb 17. doi: 10.1007/s12185-026-04178.
    PubMed     Abstract available
    
    
    
34. SHEN Y, Zhang P, He A, Wang J, et al
    Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: a retrospective cohort study.
    Int J Hematol. 2026;123:270-278.
    PubMed     Abstract available
    
    
    
35. IZUTSU K, Watanabe M, Toubai T, Tsukamoto T, et al
    Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.
    Int J Hematol. 2026;123:225-232.
    PubMed     Abstract available
    
    
    
36. KOJIMA K, Tsuge N, Yoshida S, Umebara D, et al
    Myelodysplastic neoplasms with unbalanced whole-arm translocation der(5;19)(p10;q10): association with double-hit TP53 mutations.
    Int J Hematol. 2026;123:189-195.
    PubMed     Abstract available
    
    
    January 2026
37. MAKIYAMA J, Ohno N, Jimbo K, Kawamata T, et al
    Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.
    Int J Hematol. 2026;123:52-62.
    PubMed     Abstract available
    
    
    
38. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data.
    Int J Hematol. 2026;123:24-31.
    PubMed     Abstract available
    
    
    December 2025
39. SANO H
    Overweight status and chemotherapy dose modification in pediatric leukemia: disease-specific considerations.
    Int J Hematol. 2025 Dec 28. doi: 10.1007/s12185-025-04154.
    PubMed    
    
    
    
40. MATSUI H, Takizawa J, Kojima K, Tauchi T, et al
    Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.
    Int J Hematol. 2025 Dec 28. doi: 10.1007/s12185-025-04149.
    PubMed     Abstract available
    
    
    
41. SAKAI T, Miyao K, Kiwada T, Ozaki S, et al
    Intermediate-dose cytarabine as a safer consolidation strategy for acute myeloid leukemia.
    Int J Hematol. 2025 Dec 26. doi: 10.1007/s12185-025-04141.
    PubMed     Abstract available
    
    
    
42. SHABBIR MA, Reyal Y, Newell B, Salisbury J, et al
    Emperipolesis, not hemophagocytosis: chronic myelomonocytic leukemia with neoplasia-associated Rosai-Dorfman disease.
    Int J Hematol. 2025 Dec 18. doi: 10.1007/s12185-025-04142.
    PubMed    
    
    
    
43. SUZUKI K, Takaku T, Watanabe N, Iriyama N, et al
    Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.
    Int J Hematol. 2025 Dec 13. doi: 10.1007/s12185-025-04132.
    PubMed     Abstract available
    
    
    
44. TAKAOKA K, Tanariyakul M, Miyashita A, Nishimura Y, et al
    Epidemiological survey of potential familial myelodysplastic syndromes/acute myeloid leukemia in Hawaii.
    Int J Hematol. 2025 Dec 12. doi: 10.1007/s12185-025-04135.
    PubMed     Abstract available
    
    
    
45. BAHASHWAN AS
    A meta-analysis of diagnostic challenges in Ph-like ALL at baseline: early detection strategies for personalized therapeutic interventions.
    Int J Hematol. 2025;122:803-814.
    PubMed     Abstract available
    
    
    
46. SCHWENEKER K, Lenk M, Kern W, Haferlach C, et al
    Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort.
    Int J Hematol. 2025;122:835-842.
    PubMed     Abstract available
    
    
    
47. HOSONO N, Tomiyama Y, Emori N, Isogaya K, et al
    Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study.
    Int J Hematol. 2025;122:824-834.
    PubMed     Abstract available
    
    
    
48. DOI H, Akiyama H, Matsui T, Shiogama K, et al
    Andrographolide drives dual apoptosis and ferroptosis via caspase-3 and FACL4 in T-ALL cell lines.
    Int J Hematol. 2025;122:843-855.
    PubMed     Abstract available
    
    
    November 2025
49. FUJI S, Ohmoto A
    Current status of hematopoietic cell transplantation in patients with peripheral T-cell lymphoma including adult T-cell leukemia-lymphoma.
    Int J Hematol. 2025 Nov 24. doi: 10.1007/s12185-025-04118.
    PubMed     Abstract available
    
    
    
50. OYA S, Maehiro Y
    Thrombophagocytosis by myeloid blasts in acute myeloid leukemia with biallelic CEBPA mutations.
    Int J Hematol. 2025 Nov 21. doi: 10.1007/s12185-025-04116.
    PubMed    
    
    
    
51. SHIMADA T, Takahata A, Tanaka K, Toyota S, et al
    Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: a single-center retrospective study.
    Int J Hematol. 2025 Nov 17. doi: 10.1007/s12185-025-04111.
    PubMed     Abstract available
    
    
    
52. LIU X, Zhong J, Luo M, Gu X, et al
    Chronic myeloid leukemia with atypical transcript e8a2: a case report and literature review.
    Int J Hematol. 2025 Nov 15. doi: 10.1007/s12185-025-04088.
    PubMed     Abstract available
    
    
    
53. KATAYAMA S, Moriya K, Imamura T, Tamefusa K, et al
    Outcome of chemotherapy dose reduction in overweight Japanese children with acute lymphoblastic leukemia.
    Int J Hematol. 2025 Nov 10. doi: 10.1007/s12185-025-04103.
    PubMed    
    
    
    
54. IMANAKA R, Numata H, Katsuoka Y, Uoshima N, et al
    Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study).
    Int J Hematol. 2025 Nov 7. doi: 10.1007/s12185-025-04093.
    PubMed     Abstract available
    
    
    October 2025
55. AKAHANE K, Kasai S, Tamai M, Sugita Y, et al
    Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.
    Int J Hematol. 2025;122:611-615.
    PubMed     Abstract available
    
    
    September 2025
56. TOMINAGA R, Fujiwara SI, Honda S, Yokoyama D, et al
    Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2025 Sep 18. doi: 10.1007/s12185-025-04070.
    PubMed     Abstract available
    
    
    
57. HAN W, Wang S, Zhang M, Fu S, et al
    Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.
    Int J Hematol. 2025 Sep 10. doi: 10.1007/s12185-025-04064.
    PubMed     Abstract available
    
    
    
58. TAKAHASHI H, Tanaka S, Yuza Y, Iijima-Yamashita Y, et al
    Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
    Int J Hematol. 2025 Sep 4. doi: 10.1007/s12185-025-04060.
    PubMed     Abstract available
    
    
    
59. ONO K, Horiguchi H, Iyama S, Sato K, et al
    Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms.
    Int J Hematol. 2025;122:400-412.
    PubMed     Abstract available
    
    
    August 2025
60. LIU ZY, Yan ZY, Li JF, Zhu YM, et al
    Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.
    Int J Hematol. 2025;122:295-300.
    PubMed     Abstract available
    
    
    July 2025
61. HAYASHINO K, Mochizuki N, Kawatsuki A, Fujiwara Y, et al
    Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.
    Int J Hematol. 2025 Jul 22. doi: 10.1007/s12185-025-04041.
    PubMed     Abstract available
    
    
    
62. MAKISHIMA H, Mikasa T, Isogaya K, Miyamoto T, et al
    Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.
    Int J Hematol. 2025;122:57-65.
    PubMed     Abstract available
    
    
    June 2025
63. UYGUN A, Albayrak C, Ozgen U, Dincer OS, et al
    The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
    Int J Hematol. 2025 Jun 30. doi: 10.1007/s12185-025-04027.
    PubMed     Abstract available
    
    
    
64. IMI T, Asakura H, Sato K, Yamada S, et al
    Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
    Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020.
    PubMed     Abstract available
    
    
    
65. NOSAKA K, Fukushima T
    JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9-adult T-cell leukemia-lymphoma (ATL).
    Int J Hematol. 2025 Jun 4. doi: 10.1007/s12185-025-04011.
    PubMed    
    
    
    
66. MASUDA Y, Sadato D, Toya T, Hosoda Y, et al
    Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.
    Int J Hematol. 2025;121:820-832.
    PubMed     Abstract available
    
    
    May 2025
67. TAKAHASHI N, Kikushige Y, Nakamae H, Goto T, et al
    Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.
    Int J Hematol. 2025 May 26. doi: 10.1007/s12185-025-04014.
    PubMed     Abstract available
    
    
    
68. KONISHI H, Tachibana T, Arai S, Izumi A, et al
    Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Int J Hematol. 2025 May 23. doi: 10.1007/s12185-025-04009.
    PubMed     Abstract available
    
    
    
69. IKEDA J, Shiba N, Kato S, Kunimoto H, et al
    Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.
    Int J Hematol. 2025;121:694-705.
    PubMed     Abstract available
    
    
    
70. SAKURAI Y, Yanagimachi M, Ito M, Hirose A, et al
    A case of acute promyelocytic leukemia complicated by mitochondrial disease.
    Int J Hematol. 2025 May 1. doi: 10.1007/s12185-025-03992.
    PubMed     Abstract available
    
    
    April 2025
71. OKA S, Akagi Y, Mituyoshi T, Ono K, et al
    Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient.
    Int J Hematol. 2025 Apr 29. doi: 10.1007/s12185-025-03994.
    PubMed     Abstract available
    
    
    
72. ITO T, Kamimura T, Kiguchi T, Kato K, et al
    Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
    Int J Hematol. 2025 Apr 11. doi: 10.1007/s12185-025-03978.
    PubMed    
    
    
    
73. NGUYEN T, Harama D, Tamai M, Kagami K, et al
    Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation.
    Int J Hematol. 2025 Apr 10. doi: 10.1007/s12185-025-03981.
    PubMed     Abstract available
    
    
    
74. IZUTSU K, Ishikawa T, Shimada K, Kubo K, et al
    Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenstrom macroglobulinemia and CLL/SLL.
    Int J Hematol. 2025;121:483-493.
    PubMed     Abstract available
    
    
    
75. TOKUSHIGE J, Taoka K, Nishikawa M, Jona M, et al
    Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria.
    Int J Hematol. 2025;121:543-546.
    PubMed     Abstract available
    
    
    
76. NISHIWAKI S, Terakura S, Morishita T, Goto T, et al
    Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.
    Int J Hematol. 2025;121:494-503.
    PubMed     Abstract available
    
    
    March 2025
77. KOH K, Kosaka Y, Okamoto Y, Maeda N, et al
    Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia.
    Int J Hematol. 2025 Mar 31. doi: 10.1007/s12185-025-03976.
    PubMed     Abstract available
    
    
    
78. NISHIMURA A, Tamura A, Fujikawa T, Inoue S, et al
    KMT2A-CBL fusion gene in the first reported case of T-cell acute lymphoblastic leukemia associated with Wiedemann-Steiner syndrome.
    Int J Hematol. 2025 Mar 28. doi: 10.1007/s12185-025-03975.
    PubMed     Abstract available
    
    
    
79. YOSHIKAWA T, Ishida H, Watanabe A, Yuza Y, et al
    Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.
    Int J Hematol. 2025 Mar 15. doi: 10.1007/s12185-025-03953.
    PubMed     Abstract available
    
    
    
80. KAMIUNTEN A, Kameda T, Sekine M, Kawano H, et al
    Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.
    Int J Hematol. 2025 Mar 11. doi: 10.1007/s12185-025-03963.
    PubMed     Abstract available
    
    
    
81. TAKAMATSU Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Int J Hematol. 2025 Mar 1. doi: 10.1007/s12185-025-03914.
    PubMed    
    
    
    February 2025
82. ABUMIYA M, Saito A, Fujioka Y, Miura M, et al
    Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.
    Int J Hematol. 2025 Feb 25. doi: 10.1007/s12185-025-03954.
    PubMed     Abstract available
    
    
    
83. ISHII S, Arakawa Y, Ishii H, Yokoyama K, et al
    A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation.
    Int J Hematol. 2025 Feb 20. doi: 10.1007/s12185-025-03944.
    PubMed     Abstract available
    
    
    
84. MATSUMOTO Y, Kato D, Muramatsu A, Sugitani M, et al
    Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations.
    Int J Hematol. 2025 Feb 19. doi: 10.1007/s12185-025-03938.
    PubMed     Abstract available
    
    
    January 2025
85. FENG LS, Li HY, Tang A, Xu ML, et al
    Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.
    Int J Hematol. 2025 Jan 23. doi: 10.1007/s12185-025-03915.
    PubMed     Abstract available
    
    
    
86. MIYAZAKI Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS).
    Int J Hematol. 2025 Jan 14. doi: 10.1007/s12185-024-03906.
    PubMed    
    
    
    
87. MIYAZAKI T, Uno S, Fujimori H, Motegi Y, et al
    Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.
    Int J Hematol. 2025;121:79-88.
    PubMed     Abstract available
    
    
    
88. SAWA M, Miyamoto T, Kim HJ, Hiramatsu Y, et al
    A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.
    Int J Hematol. 2025;121:56-67.
    PubMed     Abstract available
    
    
    December 2024
89. CHIRIAC R
    Pseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia.
    Int J Hematol. 2024 Dec 30. doi: 10.1007/s12185-024-03910.
    PubMed    
    
    
    
90. UTSUNOMIYA A, Yasunaga JI, Tabuchi T, Nakano N, et al
    A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.
    Int J Hematol. 2024 Dec 25. doi: 10.1007/s12185-024-03901.
    PubMed     Abstract available
    
    
    
91. FUJITA H
    Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03908.
    PubMed    
    
    
    
92. MAEDA Y
    Correction: JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03907.
    PubMed    
    
    
    
93. ARAI H, Hosono N, Chi S, Fukushima K, et al
    A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.
    Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895.
    PubMed     Abstract available
    
    
    
94. KOHSO A, Toyoda H, Hanaki R, Niwa K, et al
    Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.
    Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890.
    PubMed     Abstract available
    
    
    
95. INAMURA J, Taketani T, Mochida M, Goto T, et al
    Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.
    Int J Hematol. 2024 Dec 4. doi: 10.1007/s12185-024-03881.
    PubMed     Abstract available
    
    
    
96. SHIMONODAN H, Sakaguchi K, Ishihara T, Okamoto Y, et al
    Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial.
    Int J Hematol. 2024;120:725-734.
    PubMed     Abstract available
    
    
    November 2024
97. TAKAHASHI N, Takenaka K, Iriyama N, Kirito K, et al
    JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03865.
    PubMed    
    
    
    
98. MUTA T, Masamoto Y, Yamamoto G, Kurahashi S, et al
    Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03875.
    PubMed     Abstract available
    
    
    
99. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.
    Int J Hematol. 2024 Nov 25. doi: 10.1007/s12185-024-03880.
    PubMed     Abstract available
    
    
    
100. ISHII Y, Fujisawa S, Miyazaki T, Nakajima Y, et al
     Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.
     Int J Hematol. 2024 Nov 19. doi: 10.1007/s12185-024-03873.
     PubMed     Abstract available
     
     
     
101. SABURI M, Nishikawa T, Kawano K, Ohtsuka E, et al
     Successful complete remission after induction therapy with CPX-351 for acute myeloid leukemia with myelodysplasia-related changes accompanied by double-minute chromosomes and MYC gene amplification.
     Int J Hematol. 2024 Nov 11. doi: 10.1007/s12185-024-03876.
     PubMed    
     
     
     
102. NAKA R, Shimomura Y, Miura M, Nagai Y, et al
     Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.
     Int J Hematol. 2024 Nov 7. doi: 10.1007/s12185-024-03869.
     PubMed     Abstract available
     
     
     
103. ISHIKAWA Y
     Recent progress in AML with recurrent genetic abnormalities.
     Int J Hematol. 2024;120:525-527.
     PubMed     Abstract available
     
     
     
104. SUGIURA H, Ishikawa T, Kuroi T, Okamoto S, et al
     Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples.
     Int J Hematol. 2024;120:594-600.
     PubMed     Abstract available
     
     
     
105. ISHIKAWA Y, Ushijima Y, Kiyoi H
     Recent advances in AML with mutated NPM1.
     Int J Hematol. 2024;120:556-565.
     PubMed     Abstract available
     
     
     
106. KENNEDY VE, Smith CC
     FLT3 targeting in the modern era: from clonal selection to combination therapies.
     Int J Hematol. 2024;120:528-540.
     PubMed     Abstract available
     
     
     October 2024
107. OUCHI F, Shingai N, Najima Y, Sadato D, et al
     Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.
     Int J Hematol. 2024 Oct 26. doi: 10.1007/s12185-024-03863.
     PubMed     Abstract available
     
     
     
108. HASHIMOTO M, Kato T, Yokota K, Sakamoto H, et al
     Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.
     Int J Hematol. 2024 Oct 10. doi: 10.1007/s12185-024-03857.
     PubMed     Abstract available
     
     
     
109. CHIRIAC R
     Therapy-related acute myeloid leukemia with inv(16)(p13.1q22).
     Int J Hematol. 2024 Oct 8. doi: 10.1007/s12185-024-03858.
     PubMed    
     
     
     
110. URRUTIA S, Takahashi K
     Precision medicine in AML: overcoming resistance.
     Int J Hematol. 2024;120:439-454.
     PubMed     Abstract available
     
     
     
111. YOSHIMARU R, Minami Y
     Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML.
     Int J Hematol. 2024;120:512-514.
     PubMed     Abstract available
     
     
     
112. SAITO S, Nakazawa Y
     CAR-T cell therapy in AML: recent progress and future perspectives.
     Int J Hematol. 2024;120:455-466.
     PubMed     Abstract available
     
     
     September 2024
113. KINOSHITA M, Saito Y, Otani K, Uehara Y, et al
     Mitochondrial dynamics as a potential therapeutic target in acute myeloid leukemia.
     Int J Hematol. 2024 Sep 16. doi: 10.1007/s12185-024-03843.
     PubMed     Abstract available
     
     
     
114. HATTA Y, Izutsu K, Onizuka M, Dobashi N, et al
     JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL.
     Int J Hematol. 2024 Sep 6. doi: 10.1007/s12185-024-03836.
     PubMed    
     
     
     
115. YAMAGUCHI H
     Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.
     Int J Hematol. 2024 Sep 3. doi: 10.1007/s12185-024-03837.
     PubMed     Abstract available
     
     
     
116. MINAMI Y, Doki N, Matsuoka H, Yokota T, et al
     Asciminib in Patients With CML-CP Previously Treated With >/= 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
     Int J Hematol. 2024;120:305-313.
     PubMed     Abstract available
     
     
     
117. SUZUKI K, Koyama D, Oka Y, Sato Y, et al
     Myeloid sarcoma with plasmacytoid dendritic cell-like proliferation associated with IKZF1, ETV6 and DNMT3A mutations.
     Int J Hematol. 2024;120:382-388.
     PubMed     Abstract available
     
     
     August 2024
118. NISHIJIMA M, Ido K, Okayama Y, Okamura H, et al
     A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion.
     Int J Hematol. 2024 Aug 30. doi: 10.1007/s12185-024-03839.
     PubMed     Abstract available
     
     
     
119. GOTO H, Kada A, Ogawa C, Nishiuchi R, et al
     Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group.
     Int J Hematol. 2024 Aug 27. doi: 10.1007/s12185-024-03838.
     PubMed     Abstract available
     
     
     
120. ITO T, Kamimura T, Kiguchi T, Kato K, et al
     Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
     Int J Hematol. 2024 Aug 21. doi: 10.1007/s12185-024-03832.
     PubMed     Abstract available
     
     
     
121. NAGATA Y
     Molecular pathophysiology of germline mutations in acute myeloid leukemia.
     Int J Hematol. 2024 Aug 16. doi: 10.1007/s12185-024-03824.
     PubMed     Abstract available
     
     
     
122. URESHINO H, Takahashi N, Ikezoe T, Kameoka Y, et al
     A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).
     Int J Hematol. 2024 Aug 13. doi: 10.1007/s12185-024-03830.
     PubMed     Abstract available
     
     
     
123. OYA S, Ozawa H, Nakamura T, Mori A, et al
     CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
     Int J Hematol. 2024;120:194-202.
     PubMed     Abstract available
     
     
     
124. LU Y, Ma WB, Ren GM, Li YT, et al
     GPS2 promotes erythroid differentiation in K562 erythroleukemia cells primarily via NCOR1.
     Int J Hematol. 2024;120:157-166.
     PubMed     Abstract available
     
     
     
125. ZHANG W, Li J, Yamamoto K, Goyama S, et al
     Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency.
     Int J Hematol. 2024;120:186-193.
     PubMed     Abstract available
     
     
     July 2024
126. IKEDA S, Suzuki M, Tsunoda S, Ohta M, et al
     Dynamic changes in femoral bone marrow MRI in patients with chronic myelogenous leukemia.
     Int J Hematol. 2024 Jul 15. doi: 10.1007/s12185-024-03819.
     PubMed    
     
     
     
127. KUROSAWA S, Nakazato T
     Immunohistochemical differentiation of extramedullary acute myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm.
     Int J Hematol. 2024 Jul 10. doi: 10.1007/s12185-024-03817.
     PubMed    
     
     
     
128. OYA S, Ozawa H, Morishige S, Maehiro Y, et al
     High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
     Int J Hematol. 2024 Jul 4. doi: 10.1007/s12185-024-03814.
     PubMed     Abstract available
     
     
     
129. SAJIKI D, Yoshida N, Muramatsu H, Sakaguchi K, et al
     Clinical features of immature leukemias in children.
     Int J Hematol. 2024;120:117-127.
     PubMed     Abstract available
     
     
     May 2024
130. GONZALEZ-MANCERA MS, Lopategui J, Hoffman D, Kitahara S, et al
     B-cell prolymphocytic leukemia: an enduring bona fide entity.
     Int J Hematol. 2024 May 26. doi: 10.1007/s12185-024-03774.
     PubMed     Abstract available
     
     
     
131. ARAI S, Tachibana T, Izumi A, Takeda T, et al
     WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
     Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03795.
     PubMed     Abstract available
     
     
     
132. SHI X, Feng M, Nakada D
     Metabolic dependencies of acute myeloid leukemia stem cells.
     Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03789.
     PubMed     Abstract available
     
     
     
133. AKIYAMA H, Kantarjian H, Jabbour E, Issa G, et al
     Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
     Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03787.
     PubMed     Abstract available
     
     
     
134. KAITO Y, Imai Y
     Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
     Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778.
     PubMed     Abstract available
     
     
     
135. ITO M, Fukushima N
     Faggot cells observed in a patient with myelodysplastic syndrome with increased blasts.
     Int J Hematol. 2024;119:476-478.
     PubMed    
     
     
     April 2024
136. KATSUKI K, Tachibana T, Izumi A, Kim K, et al
     Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
     Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775.
     PubMed     Abstract available
     
     
     
137. TIEN FM, Hou HA
     CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
     Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773.
     PubMed     Abstract available
     
     
     
138. FUJITA H
     JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
     Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
     PubMed    
     
     
     
139. IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
     Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
     Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
     PubMed     Abstract available
     
     
     
140. TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al
     Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
     Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752.
     PubMed     Abstract available
     
     
     
141. NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
     Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
     Int J Hematol. 2024;119:426-431.
     PubMed     Abstract available
     
     
     March 2024
142. USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
     A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
     Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
     PubMed     Abstract available
     
     
     
143. XU J, Zong S, Sheng T, Zheng J, et al
     Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
     Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
     PubMed     Abstract available
     
     
     
144. IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al
     Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia.
     Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748.
     PubMed     Abstract available
     
     
     
145. TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al
     Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.
     Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741.
     PubMed     Abstract available
     
     
     
146. KAWAKAMI Y, Imamura M, Imai C
     Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
     Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756.
     PubMed    
     
     
     
147. MAEDA Y
     JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
     Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
     PubMed    
     
     
     
148. SANO H, Fukushima K, Yano M, Osone S, et al
     Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
     Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
     PubMed     Abstract available
     
     
     
149. XUE S, Sun HP, Huang XB, Chen X, et al
     Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
     Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729.
     PubMed     Abstract available
     
     
     
150. AN K, He Y, Tang Y, Gu X, et al
     Histiocytic sarcoma following CAR T-cell therapy: a case report.
     Int J Hematol. 2024;119:338-341.
     PubMed     Abstract available
     
     
     February 2024
151. SHIOZAWA Y, Fujita S, Nannya Y, Ogawa S, et al
     First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.
     Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724.
     PubMed     Abstract available
     
     
     
152. CHOED-AMPHAI C, Khorana J, Sathitsamitphong L, Natesirinilkul R, et al
     Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
     Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725.
     PubMed     Abstract available
     
     
     
153. YOKOYAMA Y
     Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.
     Int J Hematol. 2024 Feb 22. doi: 10.1007/s12185-023-03696.
     PubMed     Abstract available
     
     
     
154. HISADA Y
     Dysregulated hemostasis in acute promyelocytic leukemia.
     Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708.
     PubMed     Abstract available
     
     
     
155. YANAGI M, Mori M, Honda M, Mitani Y, et al
     Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
     Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701.
     PubMed     Abstract available
     
     
     
156. MARUYAMA D, Omi A, Nomura F, Touma T, et al
     Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
     Int J Hematol. 2024;119:146-155.
     PubMed     Abstract available
     
     
     
157. SCHALK E, Pelz AF
     Auer rods in mature granulocytes in peripheral blood.
     Int J Hematol. 2024;119:105-106.
     PubMed    
     
     
     
158. USUKI K, Ohtake S, Honda S, Matsuda M, et al
     Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
     Int J Hematol. 2024;119:130-145.
     PubMed     Abstract available
     
     
     January 2024
159. UEKI H, Ogawa C, Goto H, Nishi M, et al
     TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
     Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710.
     PubMed     Abstract available
     
     
     
160. OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al
     Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission.
     Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707.
     PubMed     Abstract available
     
     
     
161. KATO K, Takagi S, Takano H, Tsunoda S, et al
     A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
     Int J Hematol. 2024 Jan 18. doi: 10.1007/s12185-023-03691.
     PubMed     Abstract available
     
     
     
162. OYAKE M, Hirakuni Y, Hirano N, Suenobu S, et al
     Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute lymphoblastic leukemia without peripheral blasts.
     Int J Hematol. 2024 Jan 3. doi: 10.1007/s12185-023-03697.
     PubMed    
     
     
     
163. USUKI K, Ohtake S, Honda S, Matsuda M, et al
     Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
     Int J Hematol. 2024;119:24-38.
     PubMed     Abstract available
     
     
     
164. ITO M, Fukushima N, Fujii T, Numata M, et al
     Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2024;119:80-87.
     PubMed     Abstract available
     
     
     December 2023
165. MAKITA S, Ota S, Mishima Y, Usuki K, et al
     Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
     Int J Hematol. 2023 Dec 27. doi: 10.1007/s12185-023-03689.
     PubMed     Abstract available
     
     
     
166. ZHAO B, Yin J, Ding L, Luo J, et al
     SPAG6 regulates cell proliferation and apoptosis via TGF-beta/Smad signal pathway in adult B-cell acute lymphoblastic leukemia.
     Int J Hematol. 2023 Dec 26. doi: 10.1007/s12185-023-03684.
     PubMed     Abstract available
     
     
     
167. NUKUI J, Tachibana T, Miyazaki T, Tanaka M, et al
     Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.
     Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688.
     PubMed     Abstract available
     
     
     
168. TAKEYASU S, Morita K, Saito S, Toho M, et al
     Myeloid sarcoma and pathological fracture: a case report and review of literature.
     Int J Hematol. 2023;118:745-750.
     PubMed     Abstract available
     
     
     
169. MIKI K, Ogasawara R, Sugimura S, Sugita J, et al
     A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation.
     Int J Hematol. 2023;118:766-771.
     PubMed     Abstract available
     
     
     November 2023
170. SHIOMI I, Nakako S, Nakane T, Ogawa Y, et al
     Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
     Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678.
     PubMed     Abstract available
     
     
     
171. SAKAI Y, Ikawa Y, Takenaka M, Noguchi K, et al
     Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis.
     Int J Hematol. 2023 Nov 21. doi: 10.1007/s12185-023-03675.
     PubMed     Abstract available
     
     
     October 2023
172. FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al
     A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.
     Int J Hematol. 2023;118:472-476.
     PubMed     Abstract available
     
     
     
173. UNO S, Motegi Y, Minehata K, Aoki Y, et al
     Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
     Int J Hematol. 2023;118:432-442.
     PubMed     Abstract available
     
     
     September 2023
174. ZHANG A, Liu L, Zong S, Chang L, et al
     Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 x 10(9)/L.
     Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665.
     PubMed     Abstract available
     
     
     
175. HARA R, Machida S, Hashimoto N, Ogiya D, et al
     Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
     Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum